169
Views
11
CrossRef citations to date
0
Altmetric
ASTHMA/COPD PHARMACOTHERAPY

Asthma Therapy During the First 8 Years of Life: A PIAMA Cohort Study

, Pharm.D., Ph.D., , M.Sc., , Pharm.D., Ph.D., , Ph.D., , Ph.D., , Pharm.D., Ph.D., , M.D., Ph.D., , M.D., Ph.D., , M.D., Ph.D. & , M.D., Ph.D. show all
Pages 209-213 | Published online: 19 Feb 2010
 

Abstract

Objective. Many studies evaluated asthma medication use in children in a cross-sectional manner, yet little is known about longitudinal use patterns. This study describes the formation of a longitudinal data set on asthma medication use and shows first results regarding the prevalence and incidence of medication use. Methods. The PIAMA (Prevention and Incidence of Asthma and Mite Allergy) study is a prospective birth cohort study among 3963 Dutch children. Recruitment took place in 1996–1997. The data of the PIAMA birth cohort study were complemented with pharmacy data. Prescription information of family members was used to determine whether medication histories were complete from birth until age 8. The prevalence and incidence of asthma medication use was studied in children for whom complete medication histories were available. Results. A first prescription for asthma medication was filled before age 8 by 280 (36%) children, with 88% starting therapy before age 5. Of all children who started therapy, 91.1% received short-acting β2-agonists and 61.1% inhaled corticosteroids. Conclusion. The applied method of data collection rendered a data set including 777 children with complete medication histories for their first 8 years of life. This data set provides the opportunity to study longitudinal medication use patterns. First analyses show that asthma medication is initiated in a rather high percentage of children in this cohort and mainly at an age at which an asthma diagnosis cannot yet be firmly established.

Acknowledgments

The PIAMA study was funded by grants from the Dutch Asthma Fonds, the ZON-MW Netherlands Organization for Health Research and Development, the Stichting Astmabestrijding, and the Ministry of the Environment.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.